Aegisco Remedies Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-12-2024
- Paid Up Capital ₹ 0.69 M
as on 16-12-2024
- Company Age 12 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -13.16%
(FY 2021)
- Profit 13.51%
(FY 2021)
- Ebitda 18.73%
(FY 2021)
- Net Worth -149.23%
(FY 2021)
- Total Assets 51.95%
(FY 2021)
About Aegisco Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.69 M, as per Ministry of Corporate Affairs (MCA) records.
Gurupreet Singh, Rajneesh Kaur, and Raman Singla serve as directors at the Company.
- CIN/LLPIN
U74120UP2012PTC051201
- Company No.
051201
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aegisco Remedies Private Limited offer?
Aegisco Remedies Private Limited offers a wide range of products and services, including Common Disease Medicines, Allopathic Cough Syrup, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Ayurvedic & Herbal Extracts, Fruit Extracts, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Pharmaceutical Tablets, Ayurvedic,Herbal Products & Medicine.
Who are the key members and board of directors at Aegisco Remedies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gurupreet Singh  | Director | 26-Jun-2012 | Current |
| Rajneesh Kaur | Director | 02-Mar-2016 | Current |
| Raman Singla | Director | 12-Aug-2023 | Current |
Financial Performance of Aegisco Remedies.
Aegisco Remedies Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 13.16% decrease. The company also saw a substantial improvement in profitability, with a 13.51% increase in profit. The company's net worth observed a substantial decline by a decrease of 149.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aegisco Remedies?
In 2021, Aegisco Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aegisco Remedies?
Aegisco Remedies has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aegisco Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aegisco Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
